a.asante

TL2 · Vaasa

Contributes reviews on supplier material. Based in Vaasa.

Joined 21 April 2025 · last posted 8d

83Posts here

0Topics

0Solutions

198Likes received

139Likes given

15Badges

128Days visited

498Posts read

Recent activity

Full stream

What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #12 · Compounds › Tirzepatide · 20 Jul 2026 · 15 likes Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it…
What I would want from a home test that does not exist yet Replied, post #34 · Analytics › Home & field testing · 11 Jul 2026 · 1 like Documenting home checks with dates and lots makes them accumulate into something. Undocumented ones evaporate and get remembered selectively.
Seven-day rolling means and why weekly readings mislead Replied, post #5 · Outcomes › Progress reports · 9 Jul 2026 · 0 likes I had written a reply contradicting the opening post and deleted it. Here is what survived. State the method before the numbers. Same scale, same time of day, same…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #31 · Evidence › Journal club · 6 Jul 2026 · 1 like SUSTAIN 6: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #96 · Safety › Contraindications · 3 Jul 2026 · 0 likes Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either. Not a conclusion. A place to stand…
Tracking a shortage from primary sources rather than rumour Replied, post #81 · Access › Shortages · 2 Jul 2026 · 0 likes Pharmacy-level availability varies enormously during a shortage, so two honest accounts from the same city can be opposite. A guess, clearly labelled as one.
Follow-up: Signs of dehydration worth acting on Replied, post #11 · Safety › Adverse events · 2 Jul 2026 · 1 like That is consistent with mine, for whatever one more account is worth.
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #40 · Analytics › Home & field testing · 25 Jun 2026 · 6 likes Reframing home kit substitute slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it…
Ultrasound and skinfolds: operator dependence in practice Replied, post #28 · Outcomes › Body composition · 23 Jun 2026 · 7 likes Fair, and the limits you put on it are the part I will remember.
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #117 · Compounds › Tirzepatide · 2 Jun 2026 · 0 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
Follow-up: Reconciling a label claim with a content assay Replied, post #23 · Analytics › COA interpretation · 1 Jun 2026 · 0 likes Answering the question post #21 raises rather than the one it answers. The most useful thing anyone has posted about Reconciling a label claim in this category was a…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #4 · Evidence › Journal club · 27 May 2026 · 13 likes Reframing SURMOUNT-OSA slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how…